EA200300338A1 - Способ контрацепции и формы введения контрацептивов - Google Patents
Способ контрацепции и формы введения контрацептивовInfo
- Publication number
- EA200300338A1 EA200300338A1 EA200300338A EA200300338A EA200300338A1 EA 200300338 A1 EA200300338 A1 EA 200300338A1 EA 200300338 A EA200300338 A EA 200300338A EA 200300338 A EA200300338 A EA 200300338A EA 200300338 A1 EA200300338 A1 EA 200300338A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- reception
- administration
- during
- phase
- phases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
В заявке описаны способ гормональной контрацепции, предусматривающий большое количество практически неограниченных по времени периодов, связанных с приемом средства, и необязательно повторяющихся в течение нескольких лет, которые в каждом случае включают, по меньшей мере, один цикл приема, имеющий в течение конкретного периода приема фазу приема постоянной продолжительности, составляющую несколько дней, и паузу в приеме, составляющую несколько дней, где в течение фазы или фаз приема осуществляют ежедневное введение суточной дозы, содержащей, по меньшей мере, один обладающий контрацептивной активностью гормональный компонент, такой как эстроген и/или гестаген, и в течение паузы или пауз в приеме вводят либо плацебо, в которых отсутствуют любые гормональные компоненты, либо в течение конкретной паузы в приеме введение полностью прекращают, и продолжительность фазы или фаз приема, по меньшей мере, в течение последнего периода приема составляет, по меньшей мере, 22 дня, отличающийся тем, что продолжительность фазы или фаз приема в любой предшествующий период приема является более короткой, чем в последующий период приема; а также форма введения, предназначенная для гормональной контрацепции и, прежде всего, для обеспечения ее эффективности.Отчет о международном поиске был опубликован 2002.07.04.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10045380A DE10045380A1 (de) | 2000-09-14 | 2000-09-14 | Verfahren zur Kontrazeption und dessen Darreichungsform |
| PCT/EP2001/010207 WO2002022110A2 (en) | 2000-09-14 | 2001-09-05 | Contraception process and administration form for the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200300338A1 true EA200300338A1 (ru) | 2003-08-28 |
| EA006875B1 EA006875B1 (ru) | 2006-04-28 |
Family
ID=7656125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200300338A EA006875B1 (ru) | 2000-09-14 | 2001-09-05 | Способ контрацепции и формы введения контрацептивов |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US8076317B2 (ru) |
| EP (2) | EP1317286B1 (ru) |
| JP (3) | JP2004508398A (ru) |
| KR (3) | KR20030031185A (ru) |
| CN (1) | CN100560132C (ru) |
| AR (1) | AR030737A1 (ru) |
| AT (1) | ATE447972T1 (ru) |
| AU (2) | AU8405201A (ru) |
| BG (2) | BG107625A (ru) |
| BR (1) | BR0113902A (ru) |
| CA (1) | CA2420292C (ru) |
| CZ (1) | CZ2003723A3 (ru) |
| DE (2) | DE10045380A1 (ru) |
| EA (1) | EA006875B1 (ru) |
| EE (1) | EE200300103A (ru) |
| HK (1) | HK1060305A1 (ru) |
| HR (1) | HRP20030294A2 (ru) |
| HU (1) | HUP0301042A3 (ru) |
| IL (2) | IL154521A0 (ru) |
| ME (1) | ME00291B (ru) |
| MX (1) | MXPA03002070A (ru) |
| NO (1) | NO20031152L (ru) |
| NZ (1) | NZ524448A (ru) |
| PE (1) | PE20020425A1 (ru) |
| PL (1) | PL361161A1 (ru) |
| SK (1) | SK3102003A3 (ru) |
| TW (1) | TWI297271B (ru) |
| UA (1) | UA93650C2 (ru) |
| UY (1) | UY26932A1 (ru) |
| WO (1) | WO2002022110A2 (ru) |
| YU (1) | YU19003A (ru) |
| ZA (1) | ZA200301359B (ru) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004019743B4 (de) | 2004-04-20 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens |
| MY151322A (en) * | 2004-04-30 | 2014-05-15 | Bayer Ip Gmbh | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
| AU2011226911B2 (en) * | 2004-04-30 | 2014-06-19 | Bayer Intellectual Property Gmbh | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
| DE102004026670A1 (de) * | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat |
| DE102004026669A1 (de) * | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels |
| DE102004026679A1 (de) * | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat |
| DE102004026671A1 (de) * | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Darreichungsform zur hormonalen Kontrazeption |
| EP1655031A1 (de) | 2004-10-08 | 2006-05-10 | Schering AG | Dienogest enthaltendes Langzeit-Verfahren zur Empfängnisverhütung |
| TW200727920A (en) * | 2005-06-21 | 2007-08-01 | Organon Nv | New regimens for oral monophasic contraceptives |
| TW200744610A (en) * | 2005-06-21 | 2007-12-16 | Organon Nv | New regimens for controlled drug delivery devices for contraception |
| US8153616B2 (en) | 2005-10-17 | 2012-04-10 | Bayer Pharma Aktiengesellschaft | Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same |
| DE102006003509A1 (de) * | 2006-01-24 | 2007-07-26 | Grünenthal GmbH | Kontrazeptivum |
| EP1930010A1 (de) | 2006-10-20 | 2008-06-11 | Bayer Schering Pharma Aktiengesellschaft | Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido |
| GB0623813D0 (en) * | 2006-11-29 | 2007-01-10 | Stephenson Group Ltd | Foam reduction |
| DE102007011486A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Arzneimittel umfassend wenigstens ein Gestagen |
| EP2140860A1 (en) * | 2008-07-03 | 2010-01-06 | Bayer Schering Pharma Oy | An improved method of contraception |
| LT2782584T (lt) | 2011-11-23 | 2021-09-10 | Therapeuticsmd, Inc. | Natūralios kombinuotos pakaitinės hormonų terapijos kompozicijos ir gydymas |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| AU2015264003A1 (en) | 2014-05-22 | 2016-11-17 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2365103C3 (de) * | 1973-12-21 | 1980-08-28 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | V erwendung von Hormonen zur Kontrazeption |
| NL9301562A (nl) * | 1993-09-09 | 1995-04-03 | Saturnus Ag | Preparaat voor substitutietherapie. |
| DE4344462C2 (de) * | 1993-12-22 | 1996-02-01 | Schering Ag | Zusammensetzung für die Empfängnisverhütung |
| ES2218556T3 (es) * | 1994-11-22 | 2004-11-16 | Balance Pharmaceuticals, Inc. | Metodos de contracepcion. |
| DE19525017A1 (de) * | 1995-06-28 | 1997-01-02 | Schering Ag | Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption |
| US5897539A (en) * | 1995-09-28 | 1999-04-27 | Schering Aktiengesellschaft | Hormone replacement therapy method and hormone dispenser |
| ATE271386T1 (de) | 1996-07-26 | 2004-08-15 | Wyeth Corp | Orale einstufige empfängnisverhütungsmethode und kombinationspräparat das gestagen und estrogen enthält |
| US5898032A (en) * | 1997-06-23 | 1999-04-27 | Medical College Of Hampton Roads | Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy |
-
2000
- 2000-09-14 DE DE10045380A patent/DE10045380A1/de not_active Withdrawn
-
2001
- 2001-09-05 ME MEP-2008-376A patent/ME00291B/me unknown
- 2001-09-05 KR KR10-2003-7003667A patent/KR20030031185A/ko not_active Application Discontinuation
- 2001-09-05 AT AT01962996T patent/ATE447972T1/de not_active IP Right Cessation
- 2001-09-05 HU HU0301042A patent/HUP0301042A3/hu unknown
- 2001-09-05 PL PL36116101A patent/PL361161A1/xx not_active Application Discontinuation
- 2001-09-05 AU AU8405201A patent/AU8405201A/xx active Pending
- 2001-09-05 NZ NZ524448A patent/NZ524448A/en not_active IP Right Cessation
- 2001-09-05 US US10/380,405 patent/US8076317B2/en not_active Expired - Fee Related
- 2001-09-05 EA EA200300338A patent/EA006875B1/ru not_active IP Right Cessation
- 2001-09-05 MX MXPA03002070A patent/MXPA03002070A/es active IP Right Grant
- 2001-09-05 WO PCT/EP2001/010207 patent/WO2002022110A2/en active IP Right Grant
- 2001-09-05 EP EP01962996A patent/EP1317286B1/en not_active Expired - Lifetime
- 2001-09-05 SK SK310-2003A patent/SK3102003A3/sk not_active Application Discontinuation
- 2001-09-05 CZ CZ2003723A patent/CZ2003723A3/cs unknown
- 2001-09-05 YU YU19003A patent/YU19003A/sh unknown
- 2001-09-05 EE EEP200300103A patent/EE200300103A/xx unknown
- 2001-09-05 KR KR1020097005863A patent/KR20090033502A/ko not_active Application Discontinuation
- 2001-09-05 UA UA2003043067A patent/UA93650C2/ru unknown
- 2001-09-05 IL IL15452101A patent/IL154521A0/xx unknown
- 2001-09-05 KR KR1020107010166A patent/KR101240232B1/ko not_active IP Right Cessation
- 2001-09-05 CN CNB018155707A patent/CN100560132C/zh not_active Expired - Fee Related
- 2001-09-05 JP JP2002526362A patent/JP2004508398A/ja not_active Withdrawn
- 2001-09-05 EP EP09014071A patent/EP2153849A3/en not_active Ceased
- 2001-09-05 CA CA2420292A patent/CA2420292C/en not_active Expired - Fee Related
- 2001-09-05 AU AU2001284052A patent/AU2001284052B2/en not_active Ceased
- 2001-09-05 BR BR0113902-9A patent/BR0113902A/pt active Search and Examination
- 2001-09-05 DE DE60140462T patent/DE60140462D1/de not_active Expired - Lifetime
- 2001-09-10 PE PE2001000903A patent/PE20020425A1/es not_active Application Discontinuation
- 2001-09-11 UY UY26932A patent/UY26932A1/es not_active Application Discontinuation
- 2001-09-12 TW TW090122607A patent/TWI297271B/zh not_active IP Right Cessation
- 2001-09-14 AR ARP010104361A patent/AR030737A1/es not_active Application Discontinuation
-
2003
- 2003-02-18 IL IL154521A patent/IL154521A/en not_active IP Right Cessation
- 2003-02-19 ZA ZA200301359A patent/ZA200301359B/en unknown
- 2003-03-11 BG BG107625A patent/BG107625A/bg unknown
- 2003-03-13 NO NO20031152A patent/NO20031152L/no not_active Application Discontinuation
- 2003-04-14 HR HR20030294A patent/HRP20030294A2/hr not_active Application Discontinuation
-
2004
- 2004-05-12 HK HK04103325.6A patent/HK1060305A1/xx not_active IP Right Cessation
-
2011
- 2011-11-18 BG BG10111090A patent/BG111090A/bg unknown
- 2011-12-12 US US13/316,887 patent/US8536156B2/en not_active Expired - Fee Related
-
2012
- 2012-09-10 JP JP2012198547A patent/JP2013006866A/ja not_active Withdrawn
-
2013
- 2013-08-09 JP JP2013166891A patent/JP2013241456A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200300338A1 (ru) | Способ контрацепции и формы введения контрацептивов | |
| NO986104L (no) | Progesteron-anti-progesteron regimer | |
| EA200200392A1 (ru) | Способ получения экстракта из растения рода trichocaulon или рода hoodia, экстракт, порошковый материал и композиция на его основе и их применение для производства медикамента для лечения, профилактики или преодоления ожирения и/или подавления аппетита | |
| EA200600964A1 (ru) | Фармацевтический препарат для непрерывного гормонального лечения в течение периода времени более длительного, чем 21-28 дней, включающий две композиции эстрогена и/или прогестина | |
| RU96115165A (ru) | Средство и способ для гормональной контрацепции и/или для лечения акне | |
| KR960706344A (ko) | 호르몬 피임 및/또는 여드름 치료 수단 및 방법(means and method for hormonal contraception and/or the treatment of acne) | |
| ATE136781T1 (de) | Ovulationshemmendes mittel zur hormonalen kontrazeption | |
| UA41401C2 (ru) | Фармацевтический контрацептивный комбинированный препарат | |
| RU97106339A (ru) | Способ получения дозировочных единиц путем мокрой грануляции | |
| UA37259C2 (ru) | Активное вещество для получения лекарственных средств для лечения дисфункциональных маточных кровотечений | |
| WO2006042021B1 (en) | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens | |
| RU2000126790A (ru) | Композиция, предназначенная для лечения алкогольной и лекарственной зависимости, содержащая опиоидный антагонист и модулятор nmda рецепторного комплекса | |
| EA200200207A1 (ru) | Применение антагонистов cgrp и ингибиторов высвобождения cgrp для устранения приливов в период менопаузы | |
| BG101427A (en) | Competitive progesterone antagonists for regulating female fertility as required | |
| BR9800718B1 (pt) | composto esteróide tendo atividade contraceptiva, anti-osteoporose e para prevenir e tratar queixas da menopausa, composição farmacêutica, uso de um composto esteróide, e, processo para a preparação de um esteróide 16, 17 anelado. | |
| DK0469440T3 (da) | Faste orale applikationsformer, der som aktivt stof indeholder ifosamid | |
| RU2006114791A (ru) | Продленные режимы трехфазных контрацептивов | |
| KR970705397A (ko) | 골다공증 치료를 위한 에스트로젠 화합물 및 부갑상선 호르몬(estrogens and parathyroid hormone for treating osteoporosis) | |
| NZ504351A (en) | Contraceptive kit comprising progestogen and anti-progestogen and use in treating bleeding induced by a progestogen-only contraceptive regimen | |
| KR980700083A (ko) | 골다공증 치료 주기용 키트(KIT for Osteoporosis Treatment Cycle) | |
| RU96122561A (ru) | Способ комплексной терапии заболеваний | |
| RU98119861A (ru) | Способ лечения миодистрофии дюшенна/беккера | |
| RU2002114397A (ru) | Способ лечения мастита у коров | |
| RU99116652A (ru) | Способ лечения злокачественной лимфомы кожи | |
| RU96102023A (ru) | Гормональное средство для лечения угрей |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PD4A | Registration of transfer of a eurasian patent in accordance with the succession in title | ||
| TC4A | Change in name of a patent proprietor in a eurasian patent | ||
| PC4A | Registration of transfer of a eurasian patent by assignment | ||
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): BY RU |